Pharma BD Deal Intelligence
A $60B all-stock merger that made Pfizer the world's largest pharmaceutical company, adding Celebrex and Bextra alongside Camptosar's oncology pipeline. The blockbuster arthritis franchise drove early gains, though safety fears later forced Bextra off the market entirely.
Bextra withdrawal and Celebrex safety concerns undermined $60B mega-merger thesis
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Pfizer, already the world's largest drug maker, agreed yesterday to acquire the Pharmacia Corporation for about $60 billion in stock, a deal that would create…
Pfizer and Pharmacia announced their intention to combine operations in a significant pharmaceutical industry consolidation valued at $60 billion.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Pfizer acquired Pharmacia Corporation for approximately $60 billion in an all-stock transaction, gaining blockbuster drugs Celebrex and Bextra along with a strong oncology pipeline including Camptosar, creating the world's largest pharmaceutical company at the time.
54M US cases/yr · $8.0B Global NSAID/COX-2 Market (2002)
Arthritis and chronic pain affected over 54 million diagnosed Americans in 2002. COX-2 selective inhibitors like Celebrex and Bextra promised anti-inflammatory relief with reduced GI side effects, driving rapid adoption. Bextra was later withdrawn in 2005 over cardiovascular safety concerns.
Pfizer's $60B acquisition of Pharmacia in 2002 -- just two years after the Warner-Lambert deal -- created a pharma colossus. Celebrex and Bextra were the headline assets, but Bextra's withdrawal and Celebrex's black-box warning diminished the franchise's value significantly post-deal.
148K US cases/yr · $3.0B Global CRC Drug Market (2002)
Colorectal cancer was the third most common cancer in the US in 2002 with approximately 148,300 new diagnoses annually. Camptosar (irinotecan) was a key chemotherapy for metastatic CRC, often used in FOLFIRI regimens.
Pharmacia's oncology assets including Camptosar gave Pfizer an entry point into solid tumor oncology. The acquisition also brought Xalatan (glaucoma) and Detrol (overactive bladder), creating therapeutic breadth beyond the flagship pain franchise.
Pfizer Inc. closes acquisition/merger of Pharmacia Corporation for $60.0B, establishing strategic position and initiating integration.
Pfizer acquired Pharmacia for $60B achieving $4.2B in synergies, but Bextra withdrawal and Celebrex safety issues diminished the returns.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Pharmacia Corporation (this deal) | 2002 | $60.0B | 67 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2002 deals · Pfizer Inc. deals · Immunology deals